Last week, we successfully kicked off the Horizon 2020 funded FETOPEN program
NeutroCure (agreement No 861878).
The consortium, with partners from Friedrich-Alexander-Universitaet Erlangen
Nuernberg and Universitatsklinikum Erlangen (Germany), University of Surrey (UK), Lvivskyi Nationalnyi Medychinyi
Universytet Imeni Danyla Halytskoho (Ukraine), Centro Nacional de Investigiciones Cardiovasculares Carlos III
(F.S.P) (Spain) and Institute Gustave Roussy (France) meet in Erlangen for a day of discussions on neutrofils and
oxidation in regulation of the immune system. Redoxis look forward to the next five years of collaboration and the
research that will be the result of this. We aim to identify candidate ROS amplifier drugs and prodrugs to treat
pathogenic conditions arising due to insufficient production of reactive oxygen species (ROS), including
autoimmune disease, cancer and bone marrow ablation. We will advance these drugs from lab bench to pre-clinical
validation studies obtaining new drugs with strong therapeutic value.